# DNC Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dnc-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Daejeon-City, South Korea
- Website: www.dncbiotechnology.com
- Total disclosed funding: $0.4M
- Latest round: Seed (Feb 13, 2023)
- Investors on record: 3

## About

Based in Daejeon-City, South Korea, and founded in 2021, DNC Biotechnology Co., Ltd. operates as a medical devices and equipment company specializing in developing urine diagnosis solutions. In July 2023, D&C Biotechnology Inc. raised KRW 1 billion in pre-series A funding from Quantum Financing & Acquisition LLC, KFFI, and Hallym University Technology Holdings, with participation from Mirae Holdings. In July 2023, D&C Biotechnology Inc. raised seed funding from a Korea Tech Incubator for Startup, being selected for Accelerator Investment-Driven Tech Incubator Program. The company as of 2023, has 4 offices in Daejeon, Gangnam, Jongno, and Cheonan, a corporate-affiliated research institute in Seoul, and is led by its CEO, Park Seong-soo.

The company’s urine analysis and diagnosis solutions include deep technology-based urine chemistry precision analyzer and urine test kit to solve the existing problems of complicated and time-consuming urine test methods. The company’s devices transmit results immediately after collecting the urine sample.

## Funding rounds

- Seed, Feb 13, 2023, $0.4M — Mirae Holdings, Hisstory Venture Investment, ROWE Partners

## Investors

- Mirae Holdings (https://capitalatlas.ai/funds/mirae-holdings) — Seed
- Hisstory Venture Investment (https://capitalatlas.ai/funds/hisstory-venture-investment) — Seed
- ROWE Partners (https://capitalatlas.ai/funds/rowe-partners) — Seed